BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18575766)

  • 21. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
    Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
    Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the erbB/HER receptor family in the bovine uterus during the sexual cycle and the relation of this family to serum sex steroids.
    Sağsöz H; Ketani MA; Saruhan BG
    Biotech Histochem; 2012 Feb; 87(2):105-16. PubMed ID: 21299369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.
    Abu-Jawdeh GM; Faix JD; Niloff J; Tognazzi K; Manseau E; Dvorak HF; Brown LF
    Lab Invest; 1996 Jun; 74(6):1105-15. PubMed ID: 8667614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
    Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation.
    De Potter IY; Poumay Y; Squillace KA; Pittelkow MR
    Exp Cell Res; 2001 Dec; 271(2):315-28. PubMed ID: 11716544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are HER1/EGFR interactions with ligand free HER2 related to the effects of HER1-targeted drugs?
    Kurbel S
    Med Hypotheses; 2006; 67(6):1355-7. PubMed ID: 16890381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
    Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
    J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER1-4 protein concentrations in normal breast tissue from breast cancer patients are expressed by the same profile as in the malignant tissue.
    Olsen DA; Ostergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Jakobsen A; Brandslund I
    Clin Chem Lab Med; 2009; 47(8):977-84. PubMed ID: 19548848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
    Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
    J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Olsen DA; Corydon T; Lorentzen KA; Knudsen HJ; Jeppesen U; Brandslund I; Jakobsen A
    Clin Cancer Res; 2008 Jun; 14(11):3278-82. PubMed ID: 18519753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
    Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
    Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
    Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
    Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
    Yan XJ; Tian Y; Wang C; Wang XL; Di JM; Cheng JX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):639-43. PubMed ID: 19764562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
    Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
    Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
    Marinaş MC; Mogoş G; Ciurea R; Mogoş DG
    Rom J Morphol Embryol; 2012; 53(3):563-7. PubMed ID: 22990547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.